Dr Reddy’s produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with a particular focus on India, US, Europe and Russia. The company also conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.
Betapharm, meanwhile, is among the top five generics companies in Germany, with a market share of around 3.5%. The company markets generic drugs focusing on long-term therapy products with high prescription rates and its current portfolio comprises around 145 active ingredients in the market.
Dr Reddy’s purchase looks like a promising deal for the Indian generics company as Betapharm claims to be “the fastest-growing generics company over the past five years in the top 10 in Germany,” with a track record of successful product launches.
Commenting on the deal, Satish Reddy, COO of Dr Reddy’s Laboratories, said, “We have successfully completed the acquisition of betapharm. The strategic investment in betapharm is a step forward towards realizing Dr Reddy’s strategic intention of building a global generics business with strategic presence in all key markets.”
The sale also includes the not-for-profit Beta Institute.